IL324221A - טיפול במחלת עיניים של בלוטת התריס עם סטראליזומאב - Google Patents

טיפול במחלת עיניים של בלוטת התריס עם סטראליזומאב

Info

Publication number
IL324221A
IL324221A IL324221A IL32422125A IL324221A IL 324221 A IL324221 A IL 324221A IL 324221 A IL324221 A IL 324221A IL 32422125 A IL32422125 A IL 32422125A IL 324221 A IL324221 A IL 324221A
Authority
IL
Israel
Prior art keywords
subject
satralizumab
ted
weeks
administration
Prior art date
Application number
IL324221A
Other languages
English (en)
Original Assignee
Chugai Pharmaceutical Co Ltd
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Genentech Inc, Hoffmann La Roche filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL324221A publication Critical patent/IL324221A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL324221A 2023-04-28 2025-10-26 טיפול במחלת עיניים של בלוטת התריס עם סטראליזומאב IL324221A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363498890P 2023-04-28 2023-04-28
PCT/JP2024/016379 WO2024225417A1 (en) 2023-04-28 2024-04-26 Treatment of thyroid eye disease with satralizumab

Publications (1)

Publication Number Publication Date
IL324221A true IL324221A (he) 2025-12-01

Family

ID=93256564

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324221A IL324221A (he) 2023-04-28 2025-10-26 טיפול במחלת עיניים של בלוטת התריס עם סטראליזומאב

Country Status (8)

Country Link
EP (1) EP4701661A1 (he)
KR (1) KR20260005947A (he)
CN (1) CN121175068A (he)
AU (1) AU2024262320A1 (he)
IL (1) IL324221A (he)
MX (1) MX2025012586A (he)
TW (1) TW202448947A (he)
WO (1) WO2024225417A1 (he)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI873632B (zh) * 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途

Also Published As

Publication number Publication date
EP4701661A1 (en) 2026-03-04
KR20260005947A (ko) 2026-01-12
TW202448947A (zh) 2024-12-16
CN121175068A (zh) 2025-12-19
WO2024225417A1 (en) 2024-10-31
AU2024262320A1 (en) 2025-11-06
MX2025012586A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
Bartalena et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy
Fung et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
Sears et al. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study
US20250034265A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
US20240158518A1 (en) Pharmaceutical composition for treatment or prevention of myasthenia gravis
US20230295266A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
US20240024420A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
US20210284741A1 (en) Methods for the treatment of thyroid eye disease
KR20250134227A (ko) Fcrn 길항제를 사용한 원발성 쇼그렌 증후군 치료 방법
Fox et al. Thyroid eye disease: Management, advances, and future opportunities
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
CN119137149A (zh) 用于通过施用il-4r拮抗剂来治疗结节性痒疹的方法
WO2024225417A1 (en) Treatment of thyroid eye disease with satralizumab
Marin et al. Bilateral choroidal effusions and angle closure in the setting of systemic capillary leak syndrome from HLA-directed vaccine and pembrolizumab therapy for squamous cell carcinoma
WO2025163617A1 (en) Compositions and methods for treating sjögren's disease
US20180147280A1 (en) Method of averting opioid addiction
HK40128652A (zh) 用萨特利珠单抗治疗甲状腺眼病
US20240301058A1 (en) Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
WO2025210517A1 (en) Humanized anti-cd40 antibodies for treating sjögren's disease
US20260116985A1 (en) Methods of treating thyroid eye disease
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
KR20240014601A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
WO2024129468A1 (en) Methods for the treatment of noninfectious uveitis